What is the clinical evidence from this study?

Study design: Review. Population: Bioprosthetic valve thrombosis.

What does this research mean for the field?

Subclinical and clinical bioprosthetic valve thrombosis occurs more frequently than historically recognized, with 4-dimensional computed tomography revealing significant diagnostic, prognostic, and management challenges across surgical and transcatheter heart valves. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the pathophysiology, diagnostic modalities, clinical significance, and emerging therapeutic approaches for clinical and subclinical bioprosthetic valve thrombosis.

August 17, 2026Journal of the American College of CardiologyOpen Access

Bioprosthetic Valve Thrombosis

View Full Paper

Ask AI

Bookmark

Key result

Review outlines the clinical spectrum, diagnostic challenges, pathophysiology, and emerging therapies for bioprosthetic valve thrombosis.

Why the study?

Debate persists regarding the clinical relevance of subclinical BPV thrombosis and empirical oral anticoagulation, and systematic, prospective data are lacking on the optimal treatment approach in THV recipients.

Key Points

To review the pathophysiology, diagnostic modalities, clinical significance, and emerging therapeutic approaches for clinical and subclinical bioprosthetic valve thrombosis.
Synthesized clinical literature on bioprosthetic valve thrombosis across both surgical and transcatheter heart valve platforms.
Evaluated diagnostic findings from systematic echocardiography and high-resolution 4-dimensional computed tomographic imaging.
Analyzed current clinical debates regarding empirical oral anticoagulation and treatment strategies in heart valve recipients.
Advanced 4-dimensional computed tomography demonstrates a higher incidence of subclinical leaflet thrombosis than previously detected by echocardiography alone.
Clinical consensus remains unresolved regarding the long-term relevance of subclinical thrombosis and the routine adoption of empirical oral anticoagulation.
Prospective, systematic clinical data are currently lacking to definitively establish the optimal management protocol for transcatheter heart valve recipients.

Structured PICO

Population

Patients with surgically implanted or transcatheter bioprosthetic heart valves

Limitations

Currently no systematic, prospective data exist regarding the optimal treatment approach in THV recipients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This review highlights the emerging clinical relevance, diagnostic challenges, and therapeutic options for clinical and subclinical bioprosthetic valve thrombosis in both surgical and transcatheter heart valves.

Cite This Study

Puri et al. (2017) conducted a review in Bioprosthetic valve thrombosis. This review outlines the clinical and subclinical spectrum, diagnostic challenges, pathophysiology, and emerging therapeutic options for bioprosthetic valve thrombosis.

synapsesocial.com/papers/6a83267ebd1fa53dac838285 https://doi.org/10.1016/j.jacc.2017.02.051

View Full Paper

Ask AI

Bookmark

Bioprosthetic Valve Thrombosis

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Bioprosthetic Valve Thrombosis

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider